Your session is about to expire
← Back to Search
Anti-epileptic Drug
BHV-7000 75 mg for Epilepsy
Phase 2
Waitlist Available
Research Sponsored by Biohaven Therapeutics Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 52 weeks
Awards & highlights
Summary
A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy
Who is the study for?
This trial is for adults with refractory focal onset epilepsy who have finished the double-blind phase of previous BHV-7000 studies. Women able to bear children must test negative for pregnancy before starting.
What is being tested?
The study is testing the long-term safety and tolerability of a medication called BHV-7000 in individuals with difficult-to-treat epilepsy that starts in one area of the brain.
What are the potential side effects?
While specific side effects are not listed, 'safety and tolerability' suggest monitoring for any adverse reactions or discomfort caused by BHV-7000 over an extended period.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 52 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 52 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of Participants With Deaths, Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and moderate or severe AEs
Number of Subjects with Clinically Significant Laboratory Abnormalities
Trial Design
2Treatment groups
Experimental Treatment
Group I: BHV-7000 75 mgExperimental Treatment1 Intervention
Group II: BHV-7000 50 mgExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Biohaven Therapeutics Ltd.Lead Sponsor
10 Previous Clinical Trials
3,492 Total Patients Enrolled
3 Trials studying Epilepsy
1,022 Patients Enrolled for Epilepsy
Share this study with friends
Copy Link
Messenger